icon-folder.gif   Conference Reports for NATAP  
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
Presidio Pharmaceuticals Announces Phase 1a-1b Clinical Results with PPI-668, a Potent Pan-genotypic HCV NS5A Inhibitor
  San Francisco, CA - April 19, 2012 - Presidio Pharmaceuticals, Inc. announced results today from a Phase 1a-1b clinical trial of PPI-668, a potent, pan-genotypic HCV NS5A inhibitor being developed for the treatment of patients with chronic hepatitis C.

PPI-668 is Presidio's second NS5A inhibitor to progress to clinical testing after Phase 1 clinical evaluation of PPI-461 (results previously reported at the annual meetings of the American Association for the Study of Liver Diseases (AASLD) in 2010 and 2011). Compared to PPI-461, PPI-668 exhibits more potent activity in vitro against HCV genotypes 3a and 6a and has a superior resistance profile.

The two-part Phase 1a-1b clinical trial is being conducted at six clinical centers in the United States, New Zealand, and Australia. This study is designed to evaluate the dose-related safety and pharmacokinetics (PK) of PPI-668 in healthy adult volunteers (Part I), and then the safety, PK, and dose-related antiviral effects in treatment-naïve adult patients with HCV genotype-1 infection (Part II). Part I of the study has been successfully completed. In Part II, clinical proof-of-concept has been established with regard to the initial safety and efficacy of PPI-668 in patients with HCV genotype-1 infection.

In Part I, the study sequentially assessed single doses of 80, 160, and 320 mg in three cohorts of 8 volunteers each, randomized 6:2 to PPI-668 capsules or matching placebo; a fourth cohort received 320 mg once daily (QD) for five days. PPI-668 was well-tolerated at all tested doses with no pattern of clinical side effects or laboratory abnormalities related to treatment. Substantial blood levels of PPI-668 were achieved rapidly, and concentrations of PPI-668 that are potentially inhibitory for all major HCV genotypes were maintained for more than 24 hours, supporting evaluation of QD dosing for patients.

In Part II of the study, sequential cohorts of HCV genotype-1 patients received QD doses of 80, 160 or 240 mg for three consecutive days. Within each cohort, 10 patients were randomized 8:2 to PPI-668 or placebo. The first two cohorts have completed study treatment, with no premature discontinuations, no serious or severe clinical adverse events, and no apparent pattern of treatment-related clinical side effects or laboratory abnormalities. Partial data are available for the third dosing cohort (8/10 patients).

Rapid, marked anti-HCV efficacy has been observed for all three PPI-668 dose levels tested, with mean maximal HCV RNA reductions ranging from 3.5 to 3.7 log10 IU/mL, corresponding to viral load reductions exceeding 99.9% in the first 2-3 days of PPI-668 treatment. With proof-of-concept established for PPI-668 in genotype-1 hepatitis C patients, recruitment is currently underway to evaluate PPI-668 treatment in HCV-infected patients with genotypes 2a and 3a.

These Phase 1a-1b results support advancement to Phase 2 clinical trials in combination with other oral HCV inhibitors.